GeneType

Executive Summary

GeneType is a private San Francisco-based company developing a world-leading portfolio of personalized predictive tests that integrate genomic and clinical information to assess an individual's risk of developing various chronic diseases. Founded in 2017, the company's platform enables early detection and preventive interventions, addressing a growing demand for precision medicine in chronic disease management. By combining genetic markers with traditional clinical risk factors, GeneType aims to improve risk stratification and empower patients and physicians to make proactive healthcare decisions. The market for predictive genetic testing is expanding rapidly, driven by increasing awareness of preventive health, advances in genomics, and a shift toward value-based care. GeneType's unique approach positions it well to capture market share in the cardiometabolic, oncology, and other chronic disease segments. However, as a private company with limited public information, its execution and competitive landscape remain key uncertainties. If GeneType successfully validates its tests in large studies and secures reimbursement or partnerships with healthcare systems, it could become a significant player in the predictive health space.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation study for a flagship risk test70% success
• Q1 2027Partnership with a major health system or insurer for pilot adoption50% success
• Q2 2027Completion of Series B funding round to scale commercial operations60% success